Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) was the recipient of a significant decrease in short interest in the month of February. As of February 28th, there was short interest totalling 471,970 shares, a decrease of 45.4% from the February 15th total of 865,047 shares. Approximately 2.1% of the shares of the stock are short sold. Based on an average trading volume of 134,261 shares, the short-interest ratio is presently 3.5 days.
A number of equities analysts have recently weighed in on AGLE shares. ValuEngine raised Aeglea Bio Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, January 5th. Zacks Investment Research raised Aeglea Bio Therapeutics from a “hold” rating to a “buy” rating and set a $9.00 price objective for the company in a research note on Thursday, January 3rd. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $21.75.
A number of institutional investors have recently made changes to their positions in AGLE. Aisling Capital Management LP bought a new position in Aeglea Bio Therapeutics during the fourth quarter valued at approximately $6,506,000. Comprehensive Portfolio Management LLC bought a new position in Aeglea Bio Therapeutics during the fourth quarter valued at approximately $2,176,000. BlackRock Inc. boosted its stake in Aeglea Bio Therapeutics by 26.7% during the fourth quarter. BlackRock Inc. now owns 1,304,062 shares of the biotechnology company’s stock valued at $9,768,000 after buying an additional 275,066 shares during the last quarter. Point72 Asset Management L.P. bought a new position in Aeglea Bio Therapeutics during the third quarter valued at approximately $2,542,000. Finally, Northern Trust Corp boosted its stake in Aeglea Bio Therapeutics by 870.0% during the second quarter. Northern Trust Corp now owns 177,184 shares of the biotechnology company’s stock valued at $1,874,000 after buying an additional 158,918 shares during the last quarter. 68.43% of the stock is owned by institutional investors.
Aeglea Bio Therapeutics (NASDAQ:AGLE) last announced its quarterly earnings results on Thursday, March 7th. The biotechnology company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.27). Aeglea Bio Therapeutics had a negative net margin of 480.92% and a negative return on equity of 71.39%. On average, equities analysts anticipate that Aeglea Bio Therapeutics will post -1.7 EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Aeglea Bio Therapeutics Inc (AGLE) Short Interest Down 45.4% in February” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.tickerreport.com/banking-finance/4224725/aeglea-bio-therapeutics-inc-agle-short-interest-down-45-4-in-february.html.
Aeglea Bio Therapeutics Company Profile
Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.
Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.